For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
4
views
0
references
 Top references
cited by
82
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      347
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Immunomodulation by targeted anticancer agents.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Cancer Cell
          Title: Cancer cell
          Publisher: Elsevier BV
          ISSN (Electronic): 1878-3686
          ISSN (Print): 1535-6108
          Publication date (Electronic): Mar 08 2021
          Volume: 39
          Issue: 3
          Affiliations
          [1 ] Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
          [2 ] Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
          [3 ] Equipe Labellisée Par La Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kroemer@orange.fr.
          [4 ] Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.
          Article
          Publisher Item ID: S1535-6108(20)30601-2
          DOI: 10.1016/j.ccell.2020.11.009
          PubMed ID: 33338426
          SO-VID: 5e0db4d9-3125-4ea6-bbd6-a1fce1a58299
          History

          Keywords: BRAF,immunogenic cell death,immune checkpoint blockers,TGF-β,T(REG) cells,KRAS,EGFR,DNA damage response,CGAS signaling,CDK4/CDK6,CD8(+) cytotoxic T lymphocytes
          Data availability:
          Keywords: BRAF, immunogenic cell death, immune checkpoint blockers, TGF-β, T(REG) cells, KRAS, EGFR, DNA damage response, CGAS signaling, CDK4/CDK6, CD8(+) cytotoxic T lymphocytes

          Comments

          Comment on this article

          scite_

          Similar content347

          See all similar

          Cited by82

          See all cited by